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ation is a major indepe 
myocardial infarction 
with an increased risk of congestive heart failure, ~/entricular 
aneurysm formation, cardiac rupture and death (t-61 The 
major cause of early ventricular dilation is infarct expansion 
(2,3), which can start during the first few days after the initial 
infarction, whereas later rogressive ventricular Idilation, 
which occurs largely during the first few months (7,8), may 
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occur as a result of increased wall stress 
remodeling of botb mfarct and ~o~~~farct  
experimentai ~~~rc~~o~~ increasing wall stress exacerbates 
infarct expansion (IO), whereas conveying enzyme i
tors (1 t-14) and nitrates (,15), which reduce wall stress 
been shown to hmit 
ued for 24 to 48 h can improve ventricular 
and reduce morta!i,y (ii). Simh-ll, promis 
been &served in s 
started later after t 
Evidence is more limI?ed about he effects of nitrate 
continued beyond W 
ever, because ventricula; dilation starts early after infiirC- 
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tion, any benefits may be greatest if treatment isstarted as 
early as possible and continued for at least he 1st month 
when the majority of any dilation OCCUIY (7,8). 
The International Study of Infarct Survival (JSJS>-4 
“three-way” randomized placebo-controlled pilot study was 
therefore set up to assess the safety and tolerability Of 1 
month Of Oral captoprii therapy and 1 month of oral isosor- 
bide mononitrate treatment s arted uring ihe acute phi-se Of 
suspected acute myocardiai infarction. The present report 
describes a substudy in which the hemody namic response to
these treatments was investigated noninvarjiveiy using Dopp- 
ler echocardiography. 
Study patients. The study protocol was approved by the 
Central Oxford Research Ethics Committee, and all partici- 
pating patients gave their informed consent. Patients were 
eligible for the ISIS-4 pilot study if the symptoms of sus- 
pected acute myocardial infarction (with or without ST 
elevation on the presenting electrocardiogram (ECGH had 
started <36 h before and there were no clear indications for, 
or contraindications to, prolonged use of converting enzyme 
inhibitors or nitrates (for example, systolic blood pressure 
persistently ~90 mm Rg). Patients who were to be given 
intravenous nitrates for just the first few days were still 
eligible. The intent was to randomize patients as promptly as 
possible after admission to the hospital, but patients who 
were not eligible on admission (perhaps because of some 
contraindication such as hypotension) could be reassessed a 
few hours later and entered into the study if they were stilt 
eligible and within 36 h from symptom onset. 
Patients were entered into the trial by the responsible 
physicians, who telephoned a 24-h randomization service. 
After providing a few baseline details, they were randomly 
allocated to receive a treatment pack containing 1 month’s 
stipp:;’ L$ oral captopril (initial dose, 6.25 mg followed 2 h 
later by 12.5 mg and continuing with 12.5 mg three times 
daily), isosorbide mononitrate (initial dose 20 mg followed 
by 20 mg three times daily) or matching placebo. Apart from 
any planned short-term intravenous nitrate use, nonstudy 
nitrates and converting enzyme inhibitors were to be used 
only if a clear indication was thought to have developed. Al! 
other aspects of patient management were left entirely to the 
discretion of the responsible physician, 
Hemodynamic assessment. Patients were to be iaciujed 
in this detailed substudy of the hemodynamic response to 
treatment if after randomization but before the start of 
placebo-controlled trial treatment, they were in sinus rhythm 
and it wu technically possible to obtain a good quaJi;y 
Doppler signal. Eighty-one ofthe 123 patients randomized in 
the ISIS-4 pilot study from the John Radcliffe Hospital 
between August 1989 and July I990 fuifilled these ligibility 
criteria nd were included in the substudy. Systolic, diastolic 
and mean arterial (D f 6 - D)/3) blood pressure (by standard 
sphygmomanometer), heart rate and blood velocity in the 
ascending aorta (by Doppler e~bocardiQgraphy~ werere- 
corded immediately before the start of trial treatment, I 
after the first dose, i week after the start of trial treatme 
and at 6 weeks (that is. 2 weeks after the scheduled end of 
tria! treatment toalloH a washout period). The sssessmcnts 
cl: I week and 6 weeks were petformed 5 h after any rnor~i~g 
medication was taken. The recording and analysis of the 
Doppler signal, as well as the clinical follow-up, was per- 
formed without knowledge of the trial treatment. 
Doppler echocardiograpby was performed by a single 
observer using an Alfred (Vingmed) ultrasound generator 
lsed wave Doppler transdttcer di ected from 
window with the patient supine. The sample 
at a level just above the aortic valve (4 to 
9 cm from the suprasternal notch) and the angle usted to 
obtain the highest audible pitch and the clean velocity 
curve on the display screen. All follow-up 
ings in any particular patient were pet-for 
position with the same depth setting as a! 
ensure that the recording was from the same point in the 
aona. Stroke distance (averaged over IO beats) was obtained 
by fast Fourier transform spectral analysis of the signal to 
obtain the intensity-weighted mean velocity, which was then 
integrated over time to detive the velocity i:rtegral or stroke 
distance. This system was developed an 
John Radcliffe Hospital cardiac hemody~amic laboratory 
(27.28). It has been shown that ac’rtic ross-sectional area 
can be assumed to be constant over the short term in any 
particular patient (29,30), so that percent changes from 
baseline in stroke distance accurately reflect percent 
changes in stroke volume (taken as stroke distance muiti- 
plied by aortir, cross-sectional rea). Similarly, because 
cardiac output is equal to stroke distance times aortic area 
times heart rate, percent changes in the product of stroke 
distance and heart rate reflect percent changes in cardiac 
output. Percent changes in total systemic vascular resistance 
were estimated using the approximation that systemic vas- 
cular resistance quals mean blood pressure divided by 
cardiac output. The intraobserver variabihty for stroke dis- 
tance (expressed asthe SD of the differences between repeat 
measuremenrs 1311) was previously determined tobe 5.6% 
and the month to month reproducibility was 7.4%. 
Statistical methods, On the basis of these ::stimates of
observer variability and reproducibility, it was calculated 
(32) that a study with at least 25 patients in each treatment 
group would provide 80% power at p < 0.05 to detect he 
type of differences (i.e , 10%) in cardiac output observed in 
previous tudies (7,8). Comparisons of the percent change 
from baseiine ineach of the treatment groups compared with 
the percent change in the contro! group were made an an 
intention-to-treat b sis except when follow-up data were 
unavailable b cause ofdeath or no~atte~da~~e (see Rest&s). 
One-way analysis of variance was performed at erch time 
point and, if p was < 0.05, then two-way comparisons of
each treatment versus control were carried out using two-tail 
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aracteris ‘.. a of Patients Studied 
PP. .- .- 
EMN Placebo 
Variable (n = 27) In = 22) @a = 32) 
Before randomization 
Age 0 cl 62 r 2 62 2 3 62 r 2 
MaSale~fenaaie 237 KM I?&!6 
Hours from pain onset 13% I 12 2 2 92 L I 
Site of infarct 
Anterior 11 (41) 7 WI 14 w 
Inferior 1s (56) 14 64 I5 (47) 
me; 1 (4 1 m 3 (91 
Baseline ~emodynaml~ data 
129 r 3 135 5 5 128 -c 3 
81 c.2 82 c 3 79 r 2 
91 r 2 !I922 95 2 2 
east rate (beatslmin) 71 c 3 71 ? 2 71 +2 
Stroke distance (cm) 10.5 ” 0.6 SO.2 ‘- 0.5 9.9 0.3 + 
After randomization an 
Treatment 
Fibrinolytic 26 (96) 20 (91) 30 (94) 
Aspirin 31 (94) 
iv. lSDN 7 (261 6 (271 12 (38) 
Ret~adrenergis blocking agents I5 (56) 15 (68) 18 (56! 
Calcium antagonist 3(11) 1 0) 5 (161 
Peak enzyme @ST, Miter) 363 t 42 278 Lz 43 370 -+ 60 
Infarction confirmed 27 (loo) 31 (97) 
Cardiogenic shock 1 (41 i (Si 0 (01 
Heart failure requiring diuretics 3 (11) 3 (14) 6 (19) 
ioronary artery surgery I (4) 1 0) 2 (6) 
Stroke 0 K!) 0 (0) 1 (3) 
Death ! (4 2 (9) 2 (6) 
Data are expressed as mean value ? SE or number (%) of patients. No differences between groups were 
significant. AST = aspartate aminotransferase; P = blood pressure; NvIN = isosorblde mono&rate; iv. HSDM = 
intravenous iscsorbide din&rate. 
Student unpaired t test. AI1 
The clinical cbaracte e 81 patienti; included in 
this hemodynamic substudy are summa~zed in T 
There was good balance between the treatment gro 
the main prognostic -features recorded before randomization 
and for the baseline hemodynamic measures. T use 64 
nontrial treatment in the hospital was similar in e three 
treatment groups, with 94% of patients receiving fibrinolytic 
therapy, 99% aspirin, 31% intravenous nitrates and 59% oral 
beta-adrenergic blockiqg agents. __ “‘he use of indomethacin or 
Ibuprofen was ver;! rare and, althougb no ktrr xex available 
on spxific nis;e oa” icotrop~c agents, the incidence of cardio- 
genie shock was very Bow an ilar in the three grou 
Peak enzyme levels did not 
groups, and all but one patknt 
subsequently con rmed by enzyme or EGG changes, or 
both. 
Compliance with trial treatment was high (Table 2); 80% 
overall continu.ed treatment until discharge or death, and a 
er of patients in each trea 
m treat,mem because of hy 
he rate of use d ~5~t~a~ c 
itrates during or titer the 
was low and was 
‘Fable 2. Compliance With Trial Treatment 
Ou!come 
Started trial treatment 
Continued treatment to deoth 
or discharge 
Withdraws 
Because of hypotcnsion 
For othrr ceason 
Nontrial cfi.l or nitrate dzing 
sche&:e& t~atment period 
CEI OI mtrate after scheduled 
treatment period 
Captopril 
(n = 27) 
27 (loal 
23 (85) 
2 (7) 
I (4) 
1 (4) 
4 (151 
ISMN Piacebo 
(II = 22) (PI = 32) 
___- 
22 (Iu@ 
18 (82) 24 (75) 
i 01 2 (61 
1 (5) 3 (91 
2 (9) 3 (91 
3 (14) 5 (16) 
There were no sigtificant ditfe-ences between groups in any of thpse 
measures of comphce. Data are expressed as number (%I of patienrs. 
CEI = converting enzyme inhibitor; lSMN = isosorbide mononitrate. 
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Table 3. Percent Changes From Baseline in 
Hemodynamic Measures 
Capropril USMN Placebo 
Wents studied (no.) 
Ih 
1 wk 
bwk 
Mean arterial BP 
lh 
1 wk 
6 wk 
Heart rate 
Ih 
I wk 
6wk 
Cardiac output 
Ih 
1 wk 
6wk 
Stroke volume 
Ih 
1 wk 
6wk 
Systemic vascular resistance 
lh 
1 wk 
6 wk 
27 22 32 
22 20 26 
24 17 25 
-10 + 2* 
-8 + 3 
-I +3 
-10 ” 2” 
-7 f 3 
+I k-4 
-I ” I 
-8 2 2 
-I ?3 
t5 * 3 
t6 + St 
t2 r 5 
-3 * 2 
-1023 
-IO*6 
+I c2 
-I c4 
025 
tE c 2t 
+I8 c 4+ 
t22 + 4 
t4 e 2 
+-IO?3 
+I5 t 6 
-!9 r 3’ 
-22 + 4’ 
-142 5 
-10 + 3$ 
-3 + 4 
t4 + 6 
-1 t I 
-9 2 4 
-3 -c 4 
ti i:2 
-4 r 4 
t7 + 4 
t2 c I 
t7 c 3 
t11 c 3 
-1 2 I 
-124 
-3 + 5 
*p < 0.001, captopril versus placebo r isosorbide mononitrate v rsus 
placebo; fp< 0.05; Sp c 0.01. Data re presented as mean percent change * 
SEM. Abbreviations a  in Table I. 
Hemodynamic changes, All 81 patients who had a base,. 
lint: recording were also evaluated at1 h after the first dose, 
but a Doppler recording was obtained at I week from only 68 
I 
<ntry 1 hour 1 week 6 weeks 
Stroke Volume 
30 
1 I 
patients (22 patients allocated to captopril, 20 allocated to 
isosorbide mononitrate. 26 allocated to placebo treatment) 
and at 6 weeks fro&m 66 (24, 17 and 25, respectively). 
Complete follow-up data could not be obtained from 15 
patients: 2 (I, 0 and 1) who required coronary artery surgery, 
~(~.Qa~d~)whohadastroke,5~~,2a~d2)~~hod~ed~~(~,2 
and 2) with a technically inadequate signal and 2 (0, I and 1) 
who subsequently refused repeat assessment. None of these 
reasons for incomplete follow-up was significantly more 
common in any particular t catme~t group. 
Percent changes from baseline in mean arterial bloo 
pressure, heart rate. cardiac 
systemic vascular resistance are 
I. One hour after the first dose of trial 
arterial blood pressure was reduced by 
and the isosorbide mononitrate grou 
compared with placebo), with similar reductions in both 
systolic and diastolic pressures. By I week, however, the 
change in mean blood pressure from baseline was similar in 
all three groups and remained so after the scheduled end of 
trial treatment (‘Table 3, Fig. la). There were no significant 
differences in heart rate between groups at 1 h an 
but at 1 week there was a small increase in the captopril 
compared with the placebo group (p C 0.05, Table 3). 
One hour after the first dose, cardiac output increased 
with captopril by I3 5 3% compared with I 2 2% in the 
placebo group (1~ <0.01). By 1 week, captopril was associ- 
ated with a significan : 23 + 5% increase in cardiac output 
(p < O.Ob! vs. placebo), which persisted even after the end of 
trial treatmect (;it 6 weeks: Table 3, Fig. Ib). In contrast. no 
significant chaqe in cardiac output was observed in the 
isosorbide mononitrate group compared with the placebo 
Cardiac Output 
-10 
‘- 
Entry 1 hour 1 week 6 weeks 
-30 .+- 
1 I 
6 weeks Entry 1 nour 1 week 6 weeks 
Figure 1. Percent changes (tl 
SEMI from baseline in (a) mean 
arterial blood pressure, (b) car- 
diac output, (c) stroke volume and 
(d) systemic vascular resistance. 
The number of patients assessed 
at I h, 1 week and 6 weeks was 81, 
68 and 66, respectively. *p < 
0.05, **p c 0.01, ***p < 0.00: 
comparing captopril or isosorbide 
mononitrate (ISMN) versus pla- 
cebo. 
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shown in Figure 2. 
expansion and attenuate ve,rtricular diiation after myocar- 
dial infarction. Typically, the ~~~~~~~~g~Q~~~s~~ system is 
maximally activate within 72 b of acute myocardial infarc- 
tion (33), with infarct expansion (2,22) and ventricular dila- 
tion (8) also starting d~r~~~ these first few days. T’hereforc, It 
rlcad reduction during the very early 
~~~arct~o~ could produce greater benefit 
nt started later during the recovery 
wever, the ventricular dilation and bypertro~hy of 
ed myocardium that occur <after myocardial infr:rc- 
tion in response to increased wall stress may help to mabn- 
tain cardiac output (34); therefore, blocking these compen- 
satory mechanisms early after infarction could in theory be 
disadvantageous. Moreover, educing blood pressure inthe 
acute phase of infarcrion with these agents might have some 
adverse Rects that could outweigh any beLlefits of earlier 
vet-, indirect comparison outcome in clinical 
captopri! started 24 to 48 8) and 8 to 9 days (7) 
after Q wave infarction suggests that starting treatment 
earlier may preserve ventricular shape and function more 
effectively. For, although ventricular dilation between the 
end of the fst week after infarction and after 3 months was 
prevented to a similar extent by captopril at both times, 
dilation during the 1st week after infarction was greater than 
-20 -10 0 10 20 
%changein mean BP 
-40 -30 -20 -10 0 10 20 
%changeinmeanBP 
60 
i 
-45 1 , __&--______., 
-40 -30 -20 .I0 0 10 20 
%changeinmeanE!? 
re 2. Correlation between percent ch 
and the percent changes in mean blood pressure (BP! I h after the 
first dose in the captopril, isosorbide mononitrate ~~S~~~ and 
placebo groups. 
in the subsequent months, and early dilation was preve 
spy started at 34 to 48 h. 
rd to one half of all dd?:~ dmting the 1st 
month after admission to the btsspital wit 
myocardial i.nfarcfjon, occur on the day of 
the next day (35,361. A Zarge p
particularly those after thro 
been attributed to causes  
cardiac rupture (37) that are rel 
sion and ventricular dilation (5). C.Jnse 
treatment even by 24 to 48 
otherwise have been preve 
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pressed that reductio.., nc In blood pressure and coronary 
perfusion pressure during the acute phase of infarction might 
critically reduce myocardial perfusion, leading to infarct 
extension and, early after fibrinolysis, might increase the 
risk of reocclusion of recanalized coronary arteries (39). 
Indeed, for this reason, patients who had received Bbtino- 
lytic therapy were excluded from one study of captopril 
started in the acute phase of infarction (22). However, 
nitrates have been used widely in acute myocardiai infarc- 
tion, are well tolerated even during fibrinolysis and appear to 
produce beneficial effects not just on ventricular remodeling 
(16) but also on mortality (57). 
emodynamic effects intire present s udy. In th:: present 
study, although both isosorbide mononitrate and captopril 
reduced blood pressure rapidly, stroke volume and cardiac 
output were maintained or, with captopril, increased inthe 
acute phase. This may help to explain the clinical observa- 
tion that patients who receive vasodilators tolerate the early 
reduction i blood pressure well whether (23,24) or not (22) 
fibrinolytic therapy has been given. Both the isosorbide 
mononitrate and the captopril regimens used in this study 
produced moderate arly blood pressure reductions com- 
pared with values in the control group that did not persist 
beyond the first few days (24). Other than producing a
transient reduction in systemic vascular esistance at 1 h, 
isosorbide mononitrate did not appear to have any effects on 
the hemodynamic variables measured. Incontrast, captopril 
increased cardiac output and strnke volume and decreased 
peripheral vascular resistance throughout he l-month 
scheduled treatment period, with the increase in cardiac 
output persisting even after treatment had been stopped. 
Captopril produced reductions inafterload and preload, both 
of which are thought o be important in the remodeling 
process (6,13). This may explain the differences in effects 
between captopril and nitrates because the latter predomi- 
nantly affect preload with less influence on afterload. An- 
other explanation for the apparent lack of effect of the 
isosorbide mononitrate r gimen studied may be the devel- 
opment of tolerance tothe three-times daily dosing schedule. 
This possibility is supported by the improvements in ven- 
tricular function observed inprevious tudies of other nitrate 
regimens (16). Also, about one third of the patients in this 
study received nitrates intravemwsly, which may have made 
it more difficult o detect any elects of oral nitrates on 
cardiac function. 
Study limitations. Doppler echocardiography as been 
well validated for the assessment of cardiac output (31) and 
is a particuta.r!y useful noninvasive method for investigating 
hemodynamic changes after vasodilator therapy (40). The 
changes incardiac output and other hemodynamic variables 
were estimated indirectly from the percent changes instroke 
volume, assuming that the aortic cross-sectional area re- 
mained constant. Aortic diameter is di%colt to measure 
accurately and reproducibly, and small differences can in- 
troduce huge variations in flow calculations. However, 
changes in aortic area during a short ime period, as in this 
study, have been shown to be small even with large 
changes (29,30); so that any errors in the assessme 
hemodynamic variables are not likely to be si 
Individually stroke volume, cardiac out 
fraction are insensitive measures ofleft v 
because, for example, a dilated ventricle 
a near-normal stroke volume despite a 1 
ume (41,42). However, although the present study only 
provides information about stroke volume, the results are in 
agreement with those of Sharpe t al. (8), who found that 
stroke volume index was increased and ve~tricl~~a~ dil tion 
prevented by captopril therapy started at 24 to 
ment was given for just 4 weeks in the presen 
follow-up was con!inued for another 2weeks after the end of 
treatment. This may appear relatively short, but t 
months after infarction constitute a particularl 
period in the remodeling process. Consequently, vasodilator 
treatment during this early period may quickly produce a 
large part of any beneficial effects that might be observed 
with longer treatment. 
Clinical implications. This study shows that both capto- 
pril and isosorbide mononitrate are well tolerated 
namicaily inthe acute phase of infarction and their 
cardiac function (particularly those of captopril but perhaps 
also those of the nitrate with a regime *:. that avoids tolerance) 
appear beneficial. Current large trials df these agents involv- 
ing several tens of thousands ofpatients with acute myocnr- 
dial infarction, such as Cooperative New Scandinavian 
Enalapril Survival Study (CGNSEFISUS)-II 1251, ISIS-4 
(43), Grllppo Italian0 per Eo Studi deil:. Scpravivenzn 
Nell’lnfarto Miocardio (GISSU-3 [44] and the Chinese cap 
topril study [45]), will help to determine directly whether 
these promising hemodynamic effects translate into any 
survival advantage or provide reliable information about 
safety. 
We thank Jim Johnston for techr:!cal assistance and Gale Mead and Mavis 
King for typing the manuscript. 
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